---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Diagnosis"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Diagnosis. Topics: Guideline statements on suspicion, biomarker screening, and genetic confirmation; Biomarkers: oxysterols, PPCS and lyso-SM, and bile acids; Genetic testing: variant spectrum and limits of routine sequencing; Suspicion Index screening tools; 12 further topics. 16 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description/diagnosis"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Guideline statements on suspicion, biomarker screening, and genetic confirmation

> “Statement #9: The signs and symptoms of NPC are nonspecific, which may lead to misdiagnosis.”
> “However, the presence of cataplexy and/or saccadic eye movement abnormalities should raise suspicion of NPC and help differentiate NPC from other neurodegenerative disorders.”
> “Statement #12: Biomarker assessment should be considered the first‐line test to screen for NPC.”
> “Three classes of biochemical markers are currently in use (oxysterols, PPCS, and lyso‐SM) or development (bile acid derivatives).”
> “Typically, the diagnosis must be confirmed by deoxyribonucleic acid (DNA) sequencing, although diagnostic routes depend on tool availability.”
> “Statement #13: Any individual whose diagnosis of NPC is considered based on their clinical manifestation and/or abnormal biomarker profile should undergo genetic testing for NPC genes to confirm the diagnosis.”
> “Referral to a clinical geneticist or genetic counselor should be considered following NPC diagnosis.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-2"></a>

### Biomarkers: oxysterols, PPCS and lyso-SM, and bile acids

> “The oxysterols cholestane‐3β, 5α, 6β‐triol (C‐triol) and 7‐ketocholesterol (7‐KC) are sensitive markers of NPC, though C‐triol is more specific”
> “Striking elevations of PPCS have been reported in both NPC and ASMD, with high sensitivity for detecting both disorders but poor distinction between them.”
> “A high PPCS/lyso‐SM ratio appears to be very specific to NPC.”
> “It is highly sensitive and more specific than oxysterols (only elevated in ASMD and NPC).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-3"></a>

### Genetic testing: variant spectrum and limits of routine sequencing

> “Genetic testing (NPC1 and NPC2) is recommended to confirm NPC diagnosis”
> “However, some genetic changes (e.g., deep intronic variants, complex structural variants) may not be identified by routine sequencing methods and require complementary testing”
> “The identification of two alleles with known disease‐causing variants in either the NPC1 or NPC2 gene confirms the diagnosis of NPC.”
> “To date, about 700 different NPC1 variants have been reported, among which around 420 are considered pathogenic, with only a limited number of common or recurrent (often in certain populations) variants”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-4"></a>

### Suspicion Index screening tools

> “The Niemann‐Pick disease type C Suspicion Index (NPC‐SI) has been developed as a simple, interactive screening tool to assist HCPs in the early identification and referral of individuals suspected of NPC”
> “The NPC‐SI includes two age‐specific screening tools: one for individuals older than 4 years and another for individuals younger than four (early‐onset NPC).”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-5"></a>

### Early-onset Suspicion Index for children aged 4 years or younger

> “An early-onset NP-C SI was constructed following retrospective chart review of symptom presentation in 200 patients from nine centres comprised of 106 NP-C cases, 31 non-cases and 63 controls.”
> “Visceral symptoms were amongst the strongest predictors.”
> “Except for gelastic cataplexy and vertical supranuclear gaze palsy, central nervous system symptoms were not discriminatory in this population.”
> “The early-onset NP-C SI can help physicians, especially those with limited knowledge of NP-C, to identify patients aged ≤4 years who warrant further investigation for NP-C.”

Source: [Pineda et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4957867/)

<a id="topic-2.2.1.5-6"></a>

### Clinical findings by age group and first-line laboratory tests

> “Early infantile (age <2 years). Fetal ascites or neonatal liver disease, particularly when the latter is accompanied by prolonged cholestatic jaundice and pulmonary infiltrates.”
> “Late infantile (ages 2 to <6 years). Often presents with hypotonia and developmental delay.”
> “Note: The absence of organomegaly never eliminates the diagnosis of NPC.”
> “Assay of oxysterols has largely replaced formerly used methods of diagnosis and is now regarded as both a robust screening test and a first-line diagnostic test for NPC”
> “Bile acids derived from 7-oxocholesterol and from cholestane-3β,5α,6β-triol are also elevated in NPC, and may be useful diagnostic markers in neonates in whom oxysterols may be less reliable, as well as in older individuals”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.5-7"></a>

### Molecular testing approaches

> “Molecular genetic testing approaches can include a combination of comprehensive genomic testing (exome sequencing, genome sequencing) and gene-targeted testing (multigene panel).”
> “Note: Single-gene testing (sequence analysis of NPC1 and/or NPC2, followed by gene-targeted deletion/duplication analysis) is rarely useful and typically NOT recommended.”
> “Exome sequencing is most commonly used; genome sequencing is also possible.”
> “(2) Identification of NPC1 or NPC2 variants of uncertain significance does not establish or rule out the diagnosis.”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.5-8"></a>

### Neonatal cholestasis as a presentation of NPC

> “A study from Colorado found that 27% of infants initially diagnosed with idiopathic neonatal cholestasis (see Pediatric Genetic Cholestatic Liver Disease Overview) and 8% of all infants with cholestasis had NPC”

Source: [Bremova-Ertl and Patterson (2025)](https://www.ncbi.nlm.nih.gov/books/NBK1296/)

<a id="topic-2.2.1.5-9"></a>

### PPCS biomarker performance

> “Blood‐based biomarkers have replaced filipin staining.”
> “PPCS‐based assays now offer 100% sensitivity, 96.6% specificity in identifying NP‐C1 cases from controls and NP‐C1 carriers.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

<a id="topic-2.2.1.5-10"></a>

### Diagnostic delay by age at neurological onset: NPC Registry

> “A diagnostic delay was apparent in each of these age at neurological onset categories, with a mean delay between the appearance of first neurological symptoms and a confirmed diagnosis of NP-C of 2.5 years in early-infantile, 4.3 years in late-infantile, 6.2 years in juvenile, and 6.3 years in adolescent/adult patients (Table 2).”

Source: [Patterson et al. (2020b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7183679/)

<a id="topic-2.2.1.5-11"></a>

### Diagnostic delay in pooled cohorts

> “Non‐specific clinical presentation of NP‐C often prevents timely diagnosis, which has been shown to be delayed by a mean of 4.1 years from the onset of neurological manifestations.”

Source: [Patterson et al. (2020a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7540716/)

<a id="topic-2.2.1.5-12"></a>

### Mean age at diagnosis: International Niemann-Pick Disease Registry

> “The mean (SD) age at diagnosis was 11.2 (14.2) years.”

Source: [Bolton et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8842861/)

<a id="topic-2.2.1.5-13"></a>

### Diagnostic challenges and consequences

> “Challenges also remain in differential diagnosis, prolonged times to diagnosis, and in some cases, misdiagnosis”
> “Consequently, NPC patients may encounter delayed or restricted access to suitable management strategies.”

Source: [Hiwot et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13110917/)

<a id="topic-2.2.1.5-14"></a>

### Sponsor diagnostic program: Test for NPC and NPC GenomeComplete

> “Designed to shorten the diagnostic journey and help identify children with NPC who might otherwise never be diagnosed, the program includes NPC GenomeComplete, a Beren-sponsored genetic testing program, performed by GeneDx, that offers no-charge whole-genome sequencing, family testing, and post-test genetic counseling for eligible patients.”
> “According to the NPC Registry, it takes 2.5-4.3 years after a child’s first neurological symptom to diagnose them with I-NPC.”
> “Eligibility is through any of three pathways: clinical findings consistent with NPC, an elevated NPC biomarker, or a confirmed family history of NPC.”
> “An expedited pathway for patients requiring urgent medical decisions, returning preliminary results in approximately 48 hours for children in rapid neurological decline, against a standard turnaround of approximately four weeks”
> “Genome sequencing, which covers both coding and non-coding regions of NPC1 and NPC2”

Source: [Beren Therapeutics test for NPC press release (2026)](https://www.berentx.com/news/beren-therapeutics-launches-test-for-npc-to-help-identify-people-with-niemann-pick-disease-type-c-who-remain-undiagnosed/)

<a id="topic-2.2.1.5-15"></a>

### Newborn screening: status and bile acid dried blood spot assay

> “Newborn screening has the potential to enable earlier diagnosis prior to the onset of neurological symptoms.”
> “NP‐C is not currently included in the Australian newborn screening programmes.”

Source: [Tchan et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13193484/)

> “A high-throughput, mass spectrometry-based method was developed and validated to measure the glycine-conjugated bile acid in dried blood spots.”
> “Analysis of dried blood spots from 4992 controls, 134 NPC carriers, and 44 NPC subjects provided 100% sensitivity and specificity in the study samples.”

Source: [Jiang et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5316294/)

> “To address this critical question, we obtained the newborn DBS for already diagnosed NPC1 subjects (n=15) and carriers (n=3) residing in California, New York, and Michigan, states that archive residual DBS in biorepositories.”
> “Bile acid B, the more specific biomarker for which the fully validated DBS assay was developed, was detected in 8/15 NPC1 patients, and elevated above the cut-off in 2/15 patients (the two samples with the shortest storage time).”
> “These results demonstrate that newborn screening for NPC1 disease is feasible using bile acid biomarkers.”

Source: [Jiang et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6365165/)

<a id="topic-2.2.1.5-16"></a>

### New York pilot newborn screening study listing NPC among its conditions

| Field | Quoted record |
| --- | --- |
| Brief summary | “ScreenPlus is a consented, multi-disorder pilot newborn screening program implemented in conjunction with the New York State Newborn Screening Program that provides families the option to have their newborn(s) screened for a panel of additional conditions.” |
| Enrollment target | “Over a nine-year period, ScreenPlus aims to screen 100,000 infants born in eight high birthrate hospitals in New York for a flexible panel of rare genetic disorders.” |
| Condition | “Niemann-Pick Disease, Type C” |

Source: [ClinicalTrials.gov NCT05368038](https://clinicaltrials.gov/study/NCT05368038)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
